Active Filter(s):
Details:
The study will utilize inhaled Ampion™ to treat those suffering from respiratory distress due to COVID-19. Top-line results also showed that Ampion reduced all-cause mortality in COVID-19 respiratory distress by 78% for COVID-19 respiratory distress.
Lead Product(s): Aspartyl-alanyl-diketopiperazine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampion
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021